


Possible Complications

Unfortunately, the biopsy procedure is invasive and can result in complications. Common complications from a prostate biopsy may include bleeding, infection, sepsis/bacteremia, urinary symptoms/retention, and sexual dysfunction. 18% of men suffer complications and about 3% are hospitalized for infection within 30 days of biopsy.^{3,4,5}



Select MDx[®]
for Prostate Cancer



References:

- 1) American Cancer Society. www.cancer.org 2019
- 2) PSA Test National Cancer Institute <http://www.cancer.gov/types/prostate/psa-fact-sheet>
- 3) Gershman et al.; Eur Uro 2016
- 4) Loeb et al.; Eur Uro 2013.
- 5) Loeb et al.; J Urol. 2011.

MDxHealth is regulated under the Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) as an accredited laboratory to perform high complexity clinical testing. The SelectMDx for Prostate Cancer test was developed, and its performance characteristics determined by MDxHealth. It has not been reviewed by the U.S. Food and Drug Administration. The FDA has determined such clearance or approval is not necessary. The test is intended for use as an aid to clinicians for patient management decisions about the need for a prostate biopsy on men with clinical risk factors suggesting an increased risk for prostate cancer. Use outside of this indication has not been validated by MDxHealth. Test results should be interpreted in conjunction with other laboratory and clinical data available to the clinician and relevant guidelines on the decision for biopsy.

MDxHealth[®]
www.mdxhealth.com



15279 Alton Parkway | Suite 100 | Irvine, CA 92618
Toll Free: 866.259.5644 E: client.services@mdxhealth.com

©2019 MDxHealth S.A. All rights reserved.
MDxHealth S.A. and SelectMDx are registered trademarks of MDxHealth S.A.

IR-BROC-0067-R01

Do You Have Prostate Cancer?

Select MDx[®]
for Prostate Cancer

A non-invasive test that
only requires a urine sample.



Early Detection is Key


98%

of men diagnosed with
prostate cancer
are alive in 5 years¹

Detecting Prostate Cancer

If you have an elevated PSA test result you may be at risk for prostate cancer. However, an elevated or rising PSA may be caused by benign conditions (non-cancerous) such as prostatitis or benign prostatic hyperplasia (BPH).

Your urologist may recommend a prostate biopsy to determine if you have prostate cancer and if you need treatment.^(1,2) A transrectal ultrasound guided prostate (TRUS) biopsy is the gold standard for the diagnosis of prostate cancer.



Select MDx[®]
for Prostate Cancer

is a **non-invasive urine test** that will give you and your urologist additional prostate cancer-specific information to help determine if you should have a prostate biopsy.

Does a high PSA mean I have prostate cancer?

The prostate-specific antigen (PSA) test is the most common method to screen for prostate cancer. A high level of PSA in the bloodstream may be a warning sign for prostate cancer, however, it is important to note that there are other non-cancerous causes for an elevated or abnormal PSA level such as benign prostatic hyperplasia (BPH) or prostatitis. Because PSA can be elevated due to a variety of causes, it cannot determine if prostate cancer is present, but may indicate an increased risk for cancer so it is important that you discuss your PSA result with your urologist.

Do I need a prostate biopsy?

If you have an elevated PSA result, your urologist may recommend a prostate biopsy to determine if you have cancer. A prostate biopsy procedure is today's standard of care to assess if cancer is present or not. Although 1 in 9 men will be diagnosed with prostate cancer in their lifetime, the vast majority of men will have a benign (non-cancerous) biopsy result.⁶

Can SelectMDx help determine my risk for aggressive prostate cancer?

The SelectMDx for Prostate Cancer test will provide actionable information to help guide your doctor's decision for a prostate biopsy. If you are at very low risk for aggressive cancer, you may not require a prostate biopsy and may be followed with routine screening. However, if you are at increased risk for aggressive cancer, your urologist may suggest a biopsy, which may improve your chances for early detection and give you more treatment choices.

How does the SelectMDx test work?

SelectMDx is a non-invasive, urine (liquid biopsy) test that evaluates the expression of two cancer-related genes. When combined with other clinical risk factors, such as PSA, prostate size, and age, the SelectMDx test can help predict the likelihood that prostate cancer will be found by a biopsy and the probability of detecting clinically significant cancer.

Will my insurance cover SelectMDx?

MDxHealth will work directly with your insurance provider to coordinate coverage. Most insurances cover SelectMDx testing. If your insurance provider determines that a deductible and/or co-insurance is owed, MDxHealth offers an easy-to-enroll financial assistance program.

Contact our Patient Advocate Team for more information:

866-259-7001

Monday - Friday, 6AM - 4:30PM PT
patientfirst@mdxhealth.com

Where can I get the SelectMDx test?

If you have an elevated PSA score or other risk factors for prostate cancer and you are considering a prostate biopsy, ask your urologist about getting the SelectMDx test. Your urologist can collect a urine sample on your next office visit and send it for testing at MDxHealth's state-of-the-art CLIA-accredited, CAP-certified laboratory in Irvine, California.

For more information and to inquire about having the SelectMDx for Prostate Cancer test performed, please talk to your doctor.

SelectMDx Can Help Determine Your Need for a Biopsy

It is important to understand your risk for aggressive, potentially lethal, prostate cancer. SelectMDx can provide you and your urologist better insight on your personal risk and need for a prostate biopsy. If you are at very low risk for aggressive cancer, you may be followed with routine screening. If you are at high risk, you may benefit from a prostate biopsy and early detection.

SelectMDx[®]
for Prostate Cancer

